|
NPPA to convene stakeholder consultation meeting on Feb 5 for revising ceiling prices of coronary stents
|
|
Ramesh Shankar, Mumbai
February 01 , 2018
|
|
|
Even as the one-year validity of capping of prices of coronary stents by
the National Pharmaceutical Pricing Authority (NPPA) is fast
approaching, the national drug price regulator is convening a
stakeholder consultation meeting on February 5 for revising ceiling
prices of coronary stents in the country.
“The NPPA fixed the
ceiling prices of coronary stents vide notification dated 13th February,
2017 which is valid for one year. This decision is to be revisited now
during February, 2018. In this connection, the Authority in its meeting
to be held on 5th February, 2018 (Monday), in the Conference Room of
NPPA will hear all the stakeholders as per the date and time shown
below”, the NPPA said.
On February 5, the NPPA will hear all the
stakeholders including industry associations and NGOs working in the
health arena. They included AdvaMed, Mtal, AIMED, ISMA, AMCCI, AMCHAM,
ASSOCHAM, CM, FICCI, PHDCC&I, multinational stent manufacturing
companies, Indian stent manufacturing companies, ADEH, AIDAN, CAI, ORF,
Oxfam India and PHFI. Before that, the NPPA will have a meeting with
eminent intervention cardiologists in the country.
The NPPA, in
one of its most controversial decisions in the recent times, had fixed
the ceiling prices of coronary stents through its notification No. SO
412(E) dated February 13, 2017 which was valid for one year. The
decision needs to be revisited before February 13, 2018. In this regard,
the NPPA has already received some representations from different
quarters with regard to pricing and other related issues. As per the
notification, the NPPA had fixed the ceiling price of drug eluting
stents (DES) and bioresorbable stents at Rs.29,600 and that of bare metal stents at Rs.7,260. The prices were effective from February 14, 2017.
Earlier,
the Department of Pharmaceuticals (DoP) appointed a core committee to
look into the issue of bringing coronary stents under price control as a
large number of health groups and doctors advocating for ethical
healthcare have been seeking urgent intervention of the central
government to end the nexus between hospitals, doctors and the industry
that was resulting in exorbitant prices of life-saving coronary stents.
The
committee examined the issues relating to the essentiality of coronary
stents and in its report in April 2016 observed that there is very high
incidence of coronary artery disease (CAD) in India associated with high
morbidity and mortality; and that CAD has become a major public health
problem; and that Percutaneous Coronary Intervention (PCI) procedure
requiring coronary stent implantation is an important treatment modality
for the management of CAD, and hence coronary stents are ‘essential’
for public health.
In the light of the findings of the committee
and its recommendation, the NPPA carried out an exhaustive exercise of
consultation with stakeholders for fixing the ceiling price of coronary
stents on 4th January 2017, 5th January 2017 and 6th January 2017. The
drug regulator considered all available information and data on prices
of coronary stents in its 40th authority meeting held on 23rd January
2017. During deliberations, it was found that huge unethical markups are
charged at each stage in the supply chain of coronary stents resulting
in irrational, restrictive and exorbitant prices in a failed market
system driven by information asymmetry between the patient and doctors
pushing patients to financial misery and whereas under such
extraordinary circumstances, there is an urgent necessity, in public
interest, to fix ceiling price of coronary stents to bring respite to
patients.
Eventually, the NPPA in its authority meeting held on
February 13, 2017, after duly examining in detail and considering all
available information/data and all relevant options for price fixation
of coronary stents, under present extraordinary circumstances of a
failed and exploitative market system, decided that it is immediately
necessary to fix ceiling prices of coronary stents, in order to protect
public interest.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|